Table 1.
Characteristic | 25(OH)D <20 ng/mL (n = 77) | 25(OH)D ≥20 ng/mL (n = 337) | P Value |
---|---|---|---|
Age, mean (SD), y | 65 (16) | 67 (16) | .32 |
Sex, % | .12 | ||
Female | 38 | 49 | |
Male | 62 | 51 | |
Race, % | .02 | ||
Nonwhite | 25 | 12 | |
White | 75 | 88 | |
BMI, mean (SD), kg/m2 | 28 (6) | 26 (6) | .01 |
DCCI, mean (SD) | 3 (2) | 2 (2) | <.001 |
Total FIM, mean (SD) | 62 (12) | 60 (13) | <.001 |
Fractures, % | .32 | ||
No | 87 | 82 | |
Yes | 13 | 18 | |
Steroid use, % | .77 | ||
No | 93 | 94 | |
Yes | 7 | 6 | |
Osteoporosis/osteomalacia, % | .65 | ||
No | 90 | 88 | |
Yes | 10 | 12 | |
Vitamin D supplementation, % | <.001 | ||
None | 99 | 83 | |
<1000 IU | 1 | 15 | |
≥1000 IU | — | 2 | |
Type of patient, % | .46 | ||
Orthopedic | 30 | 29 | |
Neurological | 48 | 50 | |
Cardiac | 5 | 5 | |
Spinal cord injury | — | 3 | |
Traumatic brain injury | 17 | 13 | |
Season of ARU admission, % | .48 | ||
Summer | 54 | 59 | |
Winter | 46 | 41 | |
25(OH)D, mean (SD), ng/mL | 15 (4) | 32 (11) | <.001 |
NSMP, % | .02 | ||
No | 61 | 83 | |
Yes | 39 | 17 | |
Medications, % | |||
Acetaminophen | 90 | 96 | .10 |
NSAIDs | — | — | — |
Opioids | 92 | 77 | .003 |
Other analgesics | — | — | — |
Anticonvulsants | 6 | 10 | .30 |
Antineoplastics | — | — | — |
Antimicrobials | 5 | 3 | .47 |
Antihypertensives | 4 | 1 | .17 |
Antiretrovirals | — | — | — |
HMG-CoA reductase inhibitors | 30 | 35 | .45 |
Significant P values (<.05) are shown in bold. ARU, acute rehabilitation unit; BMI, body mass index; DCCI, Deyo-Charlson Comorbidity Index; FIM, Functional Independence Measure; NSAIDs, nonsteroidal anti-inflammatory drugs; NSMP, nonspecific musculoskeletal pain; 25(OH)D, 25-hydroxyvitamin D; —, indicates <1%. Other analgesics = gabapentin, pregabalin, tricyclic antidepressants, tizanadine, cyclobenzaprine, baclofen. Anticonvulsants = phenytoin, carbamazepine, valproic acid. Antineoplastics = taxol, tamoxifen. Antimicrobials = clotrimazole, fluconazole, rifampin. Antihypertensives = nifedipine, spironolactone. Antiretrovirals = retonovir, sequinovir.